INTRODUCTION

Chronic alcohol consumption is the most prevalent etiologic factor of hepatic fibrogenesis and cirrhosis (1). Ethanol is metabolized primarily by the alcohol dehydrogenase and the cytochrome P450 systems (2). Acetaldehyde generated by these oxidative pathways is accumulated due to slow kinetics of its oxidizing enzyme aldehyde dehydrogenase (3). Ethanol and acetaldehyde affect liver with directly generating reactive oxygen species (ROS) and indirectly producing transforming growth factor beta (TGF-β) (3). Patients with alcohol induced liver cirrhosis had significantly more leucine homozygous genotype polymorphism of TGF-β at codon 10 in Korean (4). TGF-β is a growth factor whose function is promotion of cell differentiation, fibrosis, angiogenesis, apoptosis, and suppression of cell proliferation (5, 6). TGF-β also mediates alcoholic liver diseases by hepatic apoptosis, hepatic fibrogenesis and suppression of hepatocyte proliferation (7, 8). In nervous system, TGF-β controls neuronal migration and neurite outgrowth by regulating cell adhesion proteins (12, 13).

There were many reports of increased TGF-β in ethanol treated rats in previous animal studies (14, 15). But human alcoholism study comparable has not been. In order to verify the relation between alcohol dependence and TGF-β, we measured TGF-β in patients with alcohol dependence and compared it with control subjects.

MATERIALS AND METHODS

Human subjects

We assessed the peripheral TGF-β1 levels in the plasma...
of alcohol dependence patients and healthy controls. Forty-one male patients who met the Diagnostic and Statistical Manual of Mental Disorder IV (DSM-IV) criteria for alcohol dependence were interviewed and sampled. They were all admitted to psychiatric closed ward in Hangang Sacred Heart Hospital. Two or more psychiatrists at the hospital carried out the diagnosis in a consensus procedure using all available clinical material, including a semi-structured interview based on DSM-IV. Patients were excluded from the study if they had a history of comorbid psychiatric illness, addiction to drugs other than alcohol or nicotine, physical disorders other than alcohol-related medical illness, and any neurological disease. Medical consultation were done to find any liver pathology which could affect TGF-β1 level. The comparison subjects comprised 41 unrelated healthy males who were employees of Hangang Sacred Heart Hospital. Most of the participating employees were non-drinkers; only some were occasional light drinkers (persons who drink occasionally but have lower score than cut-off value of AUDIT-K), as revealed by a drinking-habit questionnaire. The study was approved by the hospital ethics committee (Han-Gang Sacred Heart Hospital).

TGF-β1 plasma levels

Ten mL of venous blood was collected within 24 hr after admission and stored at -70°C. Plasma TGF-β1 level was determined by capture ELISA using monoclonal anti-human TGF-β1 antibody according to manufacturer’s instructions (R&D Systems Inc., Minneapolis, MN, U.S.A.). In short, 100 μL of the capture antibody was transferred to ELISA plate and incubated overnight at room temperature. After washing wells with wash buffer, the plates were blocked by 300 μL of PBS containing 5% Tween 20, 5% sucrose and 0.05% NaN3 to each well and incubated at room temperature for 1 hr. Blood plasma was added 100 μL per each well. The ELISA plate was covered with an adhesive strip and incubated 2 hr at room temperature. Streptavidin HRP (R&D Systems, 1/200 in appropriate diluent) was added 100 μL per each well. Then the plate was covered and incubated for 20 min at room temperature. After subsequent addition of substrate solution and stop solution (R&D Systems), the optical density of each well was determined within 30 min at 450 nm.

**Statistical analysis**

Numerical values are expressed as mean ± standard deviation. The Kolmogorov-Smirnov test showed that the TGF-β1 values did not fit a standard distribution curve, i.e. the distribution of the TGF-β1 levels were positively skewed. We used nonparametric Mann-Whitney test, Kruskal-Wallis test and correlation analysis with Statistica 7.0 (StatSoft Inc., Tulsa, OK, U.S.A.). The statistical significance level was set at P<0.05.

**RESULTS**

The mean age of patients with alcohol dependence and healthy controls were 45.2 ± 9.2 and 48.3 ± 10.1 yr, respectively (Table 1). There were no difference between patients of alcohol dependence and control subjects in age (P=0.15), in weight (P=0.15) and in height (P=0.84). As seen in Fig. 1, mean plasma TGF-β1 levels in the patients with alcohol dependence (1,653.11 ± 532.45 pg/mL) were higher than in the control subjects (669.87 ± 366.53 pg/mL) (P=0.000). Alcohol induced liver pathology were found with 16 patients after ultrasonography or computed tomography and consultation. Fatty liver was diagnosed in 2, alcoholic hepatitis was diagnosed in 8. Six turned out to be alcoholic cirrhosis patients. Comparison TGF-β1 level between alcohol dependence patients with or without liver pathology showed no difference (z=-0.91, P=0.36) (Fig. 2) However, when compared with control group, TGF-β1 levels showed significant difference (P=0.00) in alcohol dependence patients disregarding the presence or absence of liver pathology (P=0.00). Levels of TGF-

### Table 1. Characteristics of the normal controls and the patients with alcohol dependence

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>Patients with alcohol dependence (n=41)</th>
<th>Normal controls (n=41)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>48.3 ± 10.1</td>
<td>45.2 ± 9.2</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>167.3 ± 7.0</td>
<td>167.7 ± 7.5</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>59.7 ± 11.7</td>
<td>65.2 ± 11.7</td>
</tr>
<tr>
<td>Alcohol use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age of first use (yr)</td>
<td>21 ± 5.0</td>
<td>15-33</td>
</tr>
<tr>
<td>Average daily consumption (standard drinks)</td>
<td>10.6 ± 4.8</td>
<td>2.1-25.8</td>
</tr>
<tr>
<td>Duration of dependence (yr)</td>
<td>12.1 ± 10.4</td>
<td>1-28</td>
</tr>
</tbody>
</table>

Fig. 1. Plasma TGF-β1 level between alcohol dependence patients and normal controls.
Increased Transforming Growth Factor-beta1 in Alcohol Dependence

Fig. 2. Plasma TGF-β1 levels of alcohol dependence patients with or without liver pathology and normal controls. AD, alcohol dependence; LD, liver disease.

β1 had no correlation with mean daily alcohol consumption, age of first use, and duration of dependency (P=0.97, P=0.79, P=0.77).

DISCUSSION

Our finding verified that TGF-β1 is increased also in human alcoholism. Mean plasma TGF-β1 levels in the patients with alcohol dependence were higher than in the control subjects. There had been an increased TGF-β1 mRNA in the patients with alcoholic hepatitis and alcoholic cirrhosis. But no difference had been found between alcohol abuser and normal controls (16). We found that alcohol dependence without liver pathology (no proof of fatty liver, hepatitis, cirrhosis with ultrasonography or computed tomography) had as high TGF-β1 as patients with liver pathology (Fig. 2). It may be possible to consider TGF-β1 increase as a predictor of alcohol induced liver damage.

Chronic alcohol drinking impairs intestinal barrier and decreases hepatic clearance, resulting in increased endotoxin levels in the liver (3, 17). These endotoxin bind with lipopolysaccharide (LPS)-binding protein which binds CD14 receptor at the Kupffer cell (18). Activated Kupffer cell releases TGF-β1 in paracrine pattern that activates hepatic stellate cell which is a major fibroblastic cell type in liver. In early stage hepatic stellate cell is highly responsive to TGF-β1 and transdifferentiate into myofibroblasts (19, 20). Receptor bound TGF-β1 activate Smad family which in turn translocate into nucleus and regulates target gene expressions (21).

Increased TGF-β1 induce hepatocyte apoptosis by producing oxidative stress in rat study (8). This effect is enhanced by ethanol stimulated CYP2E1 increase, especially in perivenuous area of liver (22, 23).

Neuronal migration and neurite outgrowth are mediated by cell adhesion proteins (CAPs) such as neural cell adhesion molecule L1, and isoforms of integrin, which are regulated by TGF-β (24). Radial glia, which is a key element of guiding neuronal migration, mainly expresses TGF ligands and receptors (25-27) and also expresses cell adhesion proteins (28). TGF-β1 promotes CAP transcription and expression in low concentration, but at much higher concentration it decrease neuronal migration (12, 24). Thus, increased plasma TGF-β1 in alcoholism may suppress normal brain function.

Limitation of our study is that we checked only plasma TGF-β1 but did not check the levels in cerebrospinal fluid. TGF-β1 does not cross the intact blood-brain barrier (29). However in normal condition only choroid plexus epithelial and meningeal cells express TGF-β1, but with brain lesion much induction occurs in other cell types (30). Another limitation of our study is that all of the subjects of our study were men. So we need a study in female patients to generalize our results.

Our result, increased plasma TGF-β1 in alcohol dependence patients, suggests that alcohol induced liver damage and suppression of normal brain function may be mediated by TGF-β1. Alcohol induced liver fibrosis, hepatocyte apoptosis, and neuronal suppression may be mediated by increased TGF-β1 in alcohol dependent patients. Further study about optimal suppression of TGF-β1 that can possibly prevent alcohol induced liver damage and cognitive impairment is needed.

REFERENCES

10. Chen A. Acetaldehyde stimulates the activation of latent transforming growth factor-beta1 and induces expression of the type II recep-


20. Dooley S, Delvoux B, Strecker M, Bonzel L, Stopa M, ten Dijke P, Gressner AM. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbe-


